The World Health Organization (WHO) released its first-ever guideline on using GLP-1 medications to treat obesity.

(Reuters) -Infertility is an overlooked public health challenge and affordable treatment should be available within national health systems, the World Health Organization said on Friday in its first guideline on the topic.

The guideline reframes obesity as a chronic disease needing lifelong care, recommending GLP-1 therapies with behavioural support rather than relying on medication alone

The World Health Organization (WHO) today called on countries to make fertility care safer, fairer and more affordable for all in its first-ever global guideline for the prevention, diagnosis and treatment of infertility.

On World AIDS Day, the World Health Organization (WHO) calls on governments and partners to rapidly expand access to new WHO-approved tools including lenacapavir (LEN) to drive down infections and counter disruption to essential health services caused by cuts to foreign aid.

The World Health Organization (WHO) on Monday issued its first-ever global guidelines on the use of GLP-1 medications for treating obesity as a chronic illness. In a press release, the WHO said this guidance aimed to help reduce the “skyrocketing health costs” associated with obesity,

Ozempic-style medications have been recommended as long-term treatments for obesity under new guidelines released by the World Health Organization.